Novel concepts in treatment and prevention of bleeding

Anesthesia and Analgesia

Volumn 100, Issue 3 SUPPL., 2005, Pages 43-47

  Levy, Jerrold H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; APROTININ; ARGATROBAN; BLOOD CLOTTING FACTOR 7A; CLOPIDOGREL; DALTEPARIN; DESMOPRESSIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; FRESH FROZEN PLASMA; GLUTARALDEHYDE; HEPARIN; HIRULOG; IRON; LOW MOLECULAR WEIGHT HEPARIN; POLYMERIZED HEMOGLOBIN; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; TRANEXAMIC ACID; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ANAPHYLAXIS; BLEEDING; BLOOD CLOTTING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFLAMMATION; LUNG EMBOLISM; META ANALYSIS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; STROKE; SURGICAL PATIENT; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION;

EID: 17144405682     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Spronk HM, Govers-Riemslag JW, Ten Cate H. The blood coagulation system as a molecular machine. Bioessays 2003;25:1220-8.
2. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-6.
3. Mann KG. Thrombin formation. Chest. 2003;124(3 Suppl): 4S-10S.
4. Dacey LJ, Munoz JJ, Baribeau YR, et al. Rexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998;133:442-7.
5. Edmunds LH: The evolution of cardiopulmonary bypass: lessons to be learned. Perfusion 2002;17:243-51.
6. Levy JH. Novel intravenous antithrombins. Am Heart J 2001;141:1043-7.
7. Willerson JT. Conversion from chronic to acute coronary heart disease syndromes: role of platelets and platelet products. Tex Heart Inst J 1995;22:13-9.
8. Mojcik C, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001;71:745-54.
9. Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998;62:1817-24.
10. Strukova SM, Dugina TN, Khgatian SV, et al. Thrombin-mediated events implicated in mast cell activation. Semin Throm Hemost 1996;22:145.
11. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1995;108(suppl):258S-75.
12. Hirsh J, Heparin. N Engl J Med 1991;324:1565-74.
13. Weitz JI, Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-99.
14. Despotie GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
15. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unactionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702.
16. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.
17. Levy JH. Hemostatic agents and their safety. J Cardiothorac Anesth 1999;13(Suppl 1):6-11.
18. Levy JH. Anaphylactic reactions in anesthesia and intensive care, 2nd ed. Oxford, UK: Butterworth-Heinemann, 1992.
19. Levy JH, Zaidan JR, Faraj BA. Prospective evaluation of risk of protamine reactions in NPH insulin-dependent diabetics. Anesth Analg 1986;65:739-42.
20. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg. 2001;72:S1814-2021.
21. Stowell CP. Hemoglobin-based oxygen carriers. Curr Opin Hematol 2002;9:537-43.
22. Levy JH: Hemoglobin-based oxygen carrying solutions: close but stul so far. Anesthesiology 2000;92:639-41.
23. Cohn SM. Oxygen therapeutics in trauma and surgery. J Trauma 2003;54(5 Suppl):S193-8.
24. Levy JH, Goodnough LT, Greilich PE, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg 2002;124:35-42.
25. Sprung J, Kindscher JD, Wahr JA, et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg 2002;94:799-808.
26. Levy JH. The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. Expert Opin Biol Ther 2003;3:509-17.
27. Peters DC. Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 1999;57:233-60
28. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-53.
29. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354(9194):1940-7.
30. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003;75:S715-20.
31. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80:1013-8.
32. Levy JH, Pifarre R, Schaff H, et al. A multicenter, placebo-controlled, double-blind trial of aprotinin to reduce blood loss and the requirement of donor blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-44.
33. Alderman EL, Levy JH, Rich J, et al. Analysis of coronary graft patency after aprotinin use: results fron the International Multicenter Aprotinin Graft Patency Experience (IMAGE). J Thorac Cardiovasc Surg 1998;116:716-30.
34. Godet G, Bertrand M, Samama CM, et al. Aprotinin to decrease bleeding and intraoperative blood transfusion requirements during descending thoracic and thoracoabdominal aortic aneurysmectomy using cardiopulmonary cypass. Ann Vasc Surg 1994;8:452-6.
35. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 2000;355:1303-9.
36. Janssens M, Joris J, David JL, et al. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 1994;80:23-9.
37. Murkin JM, Shannon NA, Bourne RB, et al. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg 1995;80:343-8.
38. Murkin JM, Haig GM, Beer KJ, et al. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am 2000;82:675-84.
39. Capdevila X, Calvet Y, Biboulet P, et al. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology 1998;88:50-7.
40. Hayes A, Murphy DB, McCarroll M. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth 1996;8:357-60.
41. Kasper SM, Eisner F, Hilgers D, et al. A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Eur J Anaesthesiol 1998;15:669-75.
42. Samama CM, Langeron O, Rosencher N, et al. Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study Anesth Analga 2002;95:287-93.
43. Urban MK, Beckman J, Gordon M, et al. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine 2001;26:1152-6.
44. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coag Fibrinolysis 2000;11:5107-11.
45. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-8.
46. Wildgoose P, Nemerson Y, Hansen LL, et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992;80:25-8.
47. Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000;26:363.
48. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002;88:186-93.
49. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor Vila in patients with thrombocytopenia. Haemostasis 1996;26(suppl 1):159-64.
50. Meijer K, de Graaff WE, Daenen SM, van der Meer J. Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa. Arch Intern Med 2000;160:2216-7.
51. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-7.
52. Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha lib beta3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation Blood 2003;101:1864-70.
53. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997;113:1930-7.
54. Slappendel R, Huvers FC, Benraad B, et al. Use of recombinant factor VIIa (NovoSeven®) to reduce postoperative bleeding after total hip arthroplasry in a patient with cirrhosis and thrombocytopenias. Anesthesiology 2002;96:1525-7.
55. Svartholm E, Annerhagen V, Lanne T. Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa (letter). Anesthesiology 2002;96:1528.
56. Kale A, Bayhan G, Yalinkaya A, Yayla M. The use of recombinant factor VIIa in a primigravida with Glanzmann's thrombasthenia during delivery. J Perinat Med 2004;32:456-8.
57. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-8.
58. Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003;98:1513-5.
59. Halkos ME, Levy JH, Chen E, et al. Early experience with activated recombinant factor VII for intractable hemorrhage following cardiovascular surgery. Ann Thorac Surg. In press.
60. Zietkiewicz M, Garlicki M, Domagala J, et al. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg. 2002;123:384-5.
61. Sheth S, Dimichele D, Lee M, et al. Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia 2001;7:227-32.
62. Hendriks HG, van der Maaten JM, de Wolf J, et al. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant Factor VII. Anesth Analg 2001;93:287-9.
63. Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor Vila reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003;1:2368-73.